OBJECTIVES: Ethical and health care economic concerns surround the use of venous-arterial extracorporeal membrane oxygenation (VA-ECMO) in elderly patients. Patients requiring VA-ECMO are often in critical condition and the decision to cannulate is time-sensitive. We investigated the relationship between age and VA-ECMO outcomes to better inform this decision.
The influence of advanced age on venous-arterial extracorporeal membrane oxygenation outcomes 
INTRODUCTION
Extracorporeal life support (ECLS) using extracorporeal membrane oxygenation (ECMO) is an effective therapy for refractory cardiogenic shock. As new ECMO systems are developed and resuscitation protocols refined, patients previously not considered for ECLS are now being supported. While application of this therapy in patients with advanced age was reported to result in poor outcomes in previous small series [1, 2] , there is insufficient literature to answer the question of 'how old is too old? ' Many programmes entertain somewhat arbitrary upper age limits for ECMO use, but the immediate decision as to whether or not place an older patient on mechanical support can be complicated. Elderly patients in refractory cardiac failure often have significant and complex comorbidities that can affect outcomes. However, the decision to initiate ECMO oftentimes must be made quickly. While the left ventricular assist device literature has extensively investigated outcomes in elderly patients [3] [4] [5] , there remains a paucity of literature involving the use of ECLS in the elderly. Moreover, often-cited guidelines that outline futility are nearly 2-3 decades old [6] [7] [8] . As the population ages, the prevalence of cardiovascular disease continues to rise, and the number of elderly patients undergoing cardiac surgery increases, an understanding of the impact of advanced age on outcomes will become increasingly more relevant.
The goal of this study was to investigate the outcomes in patients of advanced age at our institution over the last 10 years and the utility of venous-arterial extracorporeal membrane oxygenation (VA-ECMO) in this population.
MATERIALS AND METHODS

Patients
We retrospectively reviewed all patients >18 years who were placed on VA-ECMO at the New York Presbyterian Hospital/ Columbia University Medical Center from January 2007 to August 2016. This study was approved by the institutional review board of Columbia University Medical Center, and individual consent was waived.
Primary end-point and predictor variables
The primary end-point was in-hospital mortality, and the primary predictor of interest was patient age at cannulation. A piecewise model was initially used to evaluate the association between age and in-hospital mortality. An age cut-off was identified by calculating the probabilities of 2 Â 2 tables formed by the outcome and dichotomized age for all possible thresholds of age and calculating the associated v 2 statistic. The age with the maximum v 2 statistic was identified as the cut-off point. Simulation study has shown that if a cut-off point exists, maximizing the v 2 statistic can recover a true threshold for a continuous random variable [9] . Other predictor variables considered were pre-existing comorbidities such as coronary artery disease, hypertension, hyperlipidaemia, diabetes mellitus, prior stroke, chronic kidney disease, chronic obstructive pulmonary disease, baseline haemoglobin, platelets, creatinine, liver function tests and lactate as well as prior cardiac surgery through a midline sternotomy.
Indications for venous-arterial extracorporeal membrane oxygenation
Our mechanical circulatory support algorithm for refractory cardiogenic shock has been previously described [10] . We characterize cardiogenic shock by a systolic blood pressure of <90 mmHg, a cardiac index of <2.0 l/min/m 2 , a pulmonary capillary wedge pressure of >16 mmHg (or evidence of pulmonary oedema on chest radiography in the absence of a pulmonary artery catheter) and evidence of end-organ hypoperfusion. These patients were rapidly evaluated by a multidisciplinary 'Shock Team' comprising cardiac surgeons, interventional and heart failure cardiologists, intensivists and nurse practitioners to determine the most suitable device for each patient [11] . ECMO initiation occurs at the bedside, in the catheterization laboratory, or in the operating room-depending on the severity of haemodynamic compromise and patient status.
Venous-arterial extracorporeal membrane oxygenation circuit and on-extracorporeal membrane oxygenation patient management
The ECMO circuit is composed of a Quadrox D oxygenator (Maquet, Wayne, NJ, USA), Rotaflow pump (Maquet) and SMARTcoated tubing (Sorin, Italy). ECMO flow was adjusted to provide systemic perfusion, which was monitored by mixed venous saturation and serum lactate, while maintaining native left ventricular (LV) ejection through the aortic valve. If clinically significant LV distension is noted after cannulation (increasing pulmonary artery diastolic pressure, worsening oxygenation, fulminant pulmonary oedema, refractory ventricular arrhythmias with enlarging LV enddiastolic diameter or significant stagnation of blood flow within the LV), the LV was vented with percutaneous femoral placement of an Impella 2.5 or CP LV assist device [12] . Patients were heparinized with a goal partial thromboplastin time of 60-80 s. Device weaning was considered when the patient demonstrated clinical improvement, as evidenced by improved end-organ function, reduction in vasoactive medication requirements and improved respiratory status. With adequate anticoagulation, device flow was temporarily decreased to 1 l/min at the bedside. Maintenance of satisfactory haemodynamics with acceptable central venous pressure (<13 mmHg) and mean arterial pressure (>70 mmHg) as well as echocardiographic parameters confirmed appropriate biventricular function, and VA-ECMO could be discontinued and subsequently explanted. When prolonged mechanical circulatory support was anticipated (generally longer than 7-10 days), VA-ECMO was aggressively converted to a short-term ventricular assist device [13, 14] . Bridging directly to an LV assist device was performed in a highly selected small number of cases.
Statistical analysis
Clinical and demographic variables were presented using standard summary statistics, including, mean ± standard deviation or median and interquartile range (25th, 75th percentile) depending on normality of distribution for continuous variables and frequencies and proportions for categorical variables. The distributions of continuous variables were tested with the Shapiro-Wilk test. To assess predictor variables and major morbidity, the v 2 or the Fisher's exact test was used for categorical variables and the Student's t-test or Mann-Whitney U-test for continuous variables. Variables with P-values < _0.10 in univariate analyses were analysed in multivariable logistic regression and summarized as odds ratios and 95% confidence intervals. We made an a priori decision to include baseline lactate level in the model because of its widely reported association with mortality in shock patients. Backwards selection was adopted for variable selection in the final model. All statistical analyses were performed with SAS version 9.4, and a P-value of <0.05 was considered statistically significant.
A propensity score-matched analysis was performed to create comparable risk groups between the advanced age and nonadvanced age groups. Patients were matched according to significant differences between the 2 groups with respect to preoperative demographic factors and comorbidities. Matching was performed using the nearest neighbour algorithm, with Group O matched to Group Y based on a 4-digit match of the propensity score.
RESULTS
A total of 370 patients were placed on VA-ECMO at our institution during the study period. There were 15 patients over the age of 72 actively undergoing cardiopulmonary resuscitation at the time of ECMO cannulation (extracorporeal cardiopulmonary resuscitation) with mortality occurring in 12 (80%) patients. For the purpose of a more unbiased analysis, these patients were removed from subsequent analyses, leaving 355 patients for subsequent analyses.
The overall median age was 59 years (interquartile range 48-68 years) and in-hospital mortality occurred in 191 (54%) patients.
Cut-off age and baseline characteristics
Based on the piecewise model, the estimated change point was at the age of 63 years (95% confidence interval 62.87-63.13, P <0.001). Prior to age 63 years, the estimated probability of death was the same across all ages-with no impact of age on the probability of death. After age 63 years, with every 1 year increase in age, the odds of death increased by 6% (odds ratio 1.06, P = 0.003). To establish an age cut-off, a distribution of the v 2 statistics was calculated for all possible cut-offs of age. The maximum v 2 was 7.374 when age was dichotomized at 72 years, generating 2 patient groups: >72 years (Group O) and < _72 years (Group Y). These data are shown in Fig. 1 . Patient characteristics are summarized in Table 1 .
There were 45 (13%) patients over 72 years old at the time of ECMO initiation (Group O), with a range of 73-90 years of age. Group O patients were more likely to have coronary disease, hypertension, hyperlipidaemia, a history of prior stroke and chronic kidney disease. They were also significantly more likely to have postcardiotomy shock as an indication for VA-ECMO with 27 (60%) patients experiencing postcardiotomy shock compared with 89 (29%) patients < _72 years (P < 0.001).
Clinical outcomes
The median length of ECMO support was 4 days (interquartile range 1-6 days), with no difference between aetiologies. Weaning from ECMO was achieved in 76% of Group Y and in 47.0% of Group O (P < 0.001). The oldest patient who survived to hospital discharge was aged 84 years. The majority of the patients were cannulated peripherally using femoral or axillary arterial cannulation with femoral venous drainage. There were 50 (14%) patients who had central cannulation: 39 (13%) patients of Group Y and 11 (24%) patients of Group O (P = 0.040), with no difference in mortality based on cannulation strategy. There were no significant differences in pre-ECMO initiation labs between the age groups ( Table 2) .
Total overall in-hospital mortality was 54%. Mortality in Group Y was 52% vs 69% in Group O (P = 0.037). Of the 12 patients over the age of 80, only 2 survived to discharge. Care was withdrawn in 69% of patients with no difference in the rates or causes of withdrawal between age groups both among those patients who died while on ECMO support and among those who died after decannulation. The most common reason for withdrawal of care was multisystem organ failure.
The most common indications for support among patients of advanced age were postcardiotomy shock and acute myocardial infarction (AMI). In-hospital mortality in those patients with postcardiotomy shock occurred in 17 (63%) Group O patients and in 49 (55%) Group Y patients (P = 0.51). In patients with AMI, 8 (80%) of the 10 Group O patients and 49 (52%) of the 95 Group Y AMI patients died during their hospitalization (P = 0.075).
Predictors of in-hospital mortality
Based on our predefined selection criteria, age >72 years, hypertension, hyperlipidaemia, chronic kidney disease, chronic obstructive pulmonary disease, prior cerebrovascular accident, coronary artery disease, postcardiotomy shock, central cannulation, acute decompensated heart failure and immediate pre-ECMO lactate were variables that were adjusted for in a multivariable logistic regression to identify significant risk factors for in-hospital mortality.
Using these risk factors, coronary artery disease, acute decompensated heart failure, baseline lactate and an age >72 were identified as independent predictors of in-hospital mortality. After adjusting for these risk factors, the odds of in-hospital mortality among patients >72 years of age was 195% higher than those < _72 years of age (odds ratio 2.71, 95% confidence interval 1.22-6.00, P = 0.014). Table 3 presents the results for the full model and the final model. Propensity score matching was performed for Group O versus Group Y using 6 variables: shock aetiology, coronary artery disease, hyperlipidaemia, hypertension, prior cerebrovascular disease and chronic kidney disease. A total of 41 pairs were identified and compared (Table 4) . Among these 2 matched groups, in-hospital mortality was significantly higher in the >72 years of age cohort at 68% (n = 28/41) compared with 43% (n = 18/41) of those < _72 years of age (P = 0.022).
DISCUSSION
The findings of this study are summarized as follows: (i) age has an impact on mortality after age 63; (ii) ECLS in-hospital mortality dramatically increased for patients over 72 years old to nearly 70% and (iii) an age over 72 years was an independent predictor of in-hospital mortality when adjusted for the higher number of comorbidities in this population.
ECLS is the most aggressive form of cardiopulmonary resuscitation for cardiogenic shock. Advancements in extracorporeal device technology have made this therapeutic modality more accessible and a rapidly growing body of literature has demonstrated an exponential increase in the use of VA-ECMO [15] [16] [17] [18] . While there has been a suggestion that, in some circumstances, the use of extracorporeal support serves as a 'bridge to nowhere' [19] , as cardiac surgical patients and the population at-large ages, Figure 1 : Odds ratios and probability of in-hospital mortality in patients on VA-ECMO. Purple lines represent observed probability of death based on 10-year interval age cohorts (median age of each cohort is presented above the lines). The shaded grey region represents the 95% confidence interval of the predicted probability of death model. The blue line represents the unadjusted odds ratios for in-hospital mortality by age. VA-ECMO: venous-arterial extracorporeal membrane oxygenation.
so too does the potential need for VA-ECMO in postcardiotomy shock, heart failure, myocardial infarction and other aetiologies of refractory cardiac failure. In this study, we included patients requiring ECMO for a variety of reasons, most commonly for postcardiotomy shock and AMI, with a particular focus on a controversial demographic-patients of advanced age.
Saxena et al. [20] described the Mayo Clinic experience with 45 postcardiotomy shock patients over the age of 70 and found an in-hospital mortality of 75.6%. Their conclusion was that perioperative cardiogenic shock in the elderly requiring extracorporeal support portends a poor prognosis but that age itself should not preclude patients from ECMO candidacy for postcardiotomy shock. Our mortality in these patients over 72 years of age was 65% and we are inclined to agree. Although postcardiotomy shock patients are acutely and severely ill due to surgical trauma and subsequent related complications, patients undergoing nonemergent cardiac surgery are presumably deemed, preoperatively, to be capable of withstanding the stress of a surgical intervention and thereby may have the reserve to tolerate extracorporeal support. Compared with postcardiotomy shock patients, elderly patients with AMI who were deemed to be suitable candidates for VA-ECMO had a worse morality rate-reaching 80%. Although subgroup analyses of shock aetiology-based outcomes are beyond the scope of this article, this observation is interesting, given that the existing literature cites postcardiotomy shock as having the worst outcome compared with cardiogenic shock from other aetiologies [14, 21, 22] . In cases of AMI, patients are often in cardiopulmonary arrest when they arrive at the hospital, and clinicians have insufficient time and clinical information about the patient's risk factors to make well-informed decisions. Within our old age cohort, close to 40% of AMI patients underwent extracorporeal cardiopulmonary resuscitation and mortality occurred in two-thirds of these patients. An extracorporeal life support organization (ELSO) registry database investigation by Mendiratta et al. [23] demonstrated that extracorporeal cardiopulmonary resuscitation in patients of advanced age (median age 70 years) was associated with 78% mortality. Again, these results do not preclude all patients of advanced age from cannulation but may better inform emergent decision-making. Previous studies have suggested that age itself, regardless of comorbidities, should not preclude patients from being candidates for ECLS with VA-ECMO [1, 20, 24] . While we are not suggesting that advanced age be a contraindication to VA-ECMO, it is notable that mortality rates in our study accelerated in >72-year-old group to nearly 70% and reached 80% in those with AMI. Moreover, both our multivariable logistic regression and propensity-matched cohort comparisons confirmed that advanced age was an influential predictor of in-hospital mortality in patients on VA-ECMO. Advanced age patients are likely to have risk profiles that were not measured in this study such as functional capacity, physiological reserve and disqualification from more definitive cardiac replacement therapies. Many of these variables are not easily measurable in the current health care setting. However, the evaluation of frailty has become the standard practice in transcatheter aortic valve replacement, where its presence may adversely impact long-term post-procedural outcomes [25, 26] . Frailty has not been well defined in the extracorporeal support literature, but it is imperative to be able to identify such patients, particularly those of older age for whom the prospect of mortality is already high to better guide decision-making.
As the field of mechanical circulatory support continues to advance, careful patient selection among the elderly population will become increasingly important. While biological age, alone, should be used cautiously-merely as one of multiple clinically relevant factors in the decision-making process-it is important to remember that advanced age is frequently accompanied by other influential comorbidities. This high level of collinearity should be taken into careful consideration at VA-ECMO consultation in which the initiation decision must be made with limited information and time. Future studies will need to develop risk stratification models to delineate those elderly patients who will benefit from ECLS and for those in whom support is futile.
Limitations
There are several limitations to this investigation. First, the age cut-off is data driven and has not been validated either internally or externally. In addition, using dichotomized age instead of continuous variables might result in loss of information. Second, the retrospective nature of this study subjects it to limitations inherent in all observational investigations. Third, these data were derived from a single, high-volume institution with limited sample sizes, which may limit overall generalizability and the feasibility to draw conclusions. We also lack follow-up quality of life and functional data on patients at discharge, which limits the scope of post-discharge outcomes analysis. Finally, conclusions drawn on our global in-hospital mortality data might minimize aetiology-specific differences among patients. We have tried to control for this by adjusting for the aetiologies significantly associated with mortality in our multivariable regression model.
CONCLUSION
In conclusion, ECLS offers a means of resuscitation for patients experiencing refractory cardiogenic shock but is associated with considerable mortality in patients of advanced age. Whether this mortality rate is prohibitive for this therapy will be better informed by future multi-institutional trials though it will, ultimately, be up to the health care team, which must consider each patient's clinical scenario to determine how age might impact the most appropriate therapeutic approach. Further studies are needed to assess the effect of advanced age as well as the impact of cost and long-term functional outcomes.
